Neumora announced that it has received $500 million in a round of funding led by Arch Venture Partners, L.P. on October 7, 2021. The company issued Common shares for gross proceeds of $100 million to new investor Amgen Inc. The transaction included participation from Alexandria Venture Investments, LLC, Altitude Life Science Ventures, Catalio Capital Management, LP, Impresa Management LLC., The Invus Group, LLC, Logos Capital LLC, Mubadala Capital, Newpath Management, L.P., Polaris Partners L.P., reMind Capital Ltd., SoftBank Vision Fund 2, a fund managed by SoftBank Investment Advisers (UK) Limited, Citadel Multi-Strategy Equities Master Fund Ltd., a fund managed by Citadel Advisors LLC, Waycross Ventures and other undisclosed investors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
270 USD | +0.22% | +0.39% | -6.26% |
Apr. 26 | Amgen to Submit Thyroid Eye Disease Treatment Marketing Authorization Application in Europe | MT |
Apr. 26 | Amgen to Seek European OK of Thyroid Eye Disease Drug Tepezza | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.26% | 145B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-11.77% | 144B |
- Stock Market
- Equities
- AMGN Stock
- News Amgen Inc.
- Neumora Therapeutics, Inc. announced that it has received $500 million in funding from a group of investors